Edition:
United Kingdom

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

33.47USD
15 Dec 2017
Change (% chg)

$0.33 (+1.00%)
Prev Close
$33.14
Open
$33.19
Day's High
$33.83
Day's Low
$32.89
Volume
1,601,292
Avg. Vol
340,734
52-wk High
$37.30
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad Genetics posts Q1 adjusted earnings per share $0.26
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal first-quarter 2018 financial results.Q1 adjusted earnings per share $0.26.Q1 GAAP earnings per share $1.15.Q1 revenue $190.2 million versus I/B/E/S view $183.4 million.Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees ‍fiscal year 2018 revenue $750 million to $770 million​.Myriad Genetics Inc sees ‍fiscal year 2018 earnings per share $1.41-$1.46​.Myriad Genetics Inc sees ‍fiscal year 2018 adjusted earnings per share $1.00-$1.05​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 revenue $187 million to $189 million​.Myriad Genetics Inc sees ‍fiscal second-quarter 2018 earnings per share $0.08-$0.10; sees fiscal second-quarter 2018 adjusted earnings per share $0.22-$0.24​.FY2018 earnings per share view $1.03, revenue view $764.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.25, revenue view $189.9 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Myriad Genetics Inc :Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer.Myriad Genetics Inc - submitted BRACAnalysis CDX in Japan for review by PMDA and marketing approval by Ministry Of Health, Labor and Welfare​.Myriad Genetics Inc - ‍submitted marketing approval as a companion diagnostic to olaparib for use in HER2- metastatic breast cancer patients​.  Full Article

Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Myriad Genetics Inc :Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer.Myriad Genetics Inc - ‍Myriad expects FDA'S priority review process to conclude in fiscal third-quarter 2018​.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Myriad Genetics to enter into a credit agreement
Thursday, 1 Sep 2016 

Myriad Genetics Inc : Says on August 31 co entered into a credit agreement . Pursuant to credit agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million .Proceeds of term loans used to finance acquisition of Assurex ,refinance certain existing indebtedness of Assurex and its units.  Full Article

Myriad Genetics reports Q4 earnings per share $0.32
Tuesday, 9 Aug 2016 

Myriad Genetics : Reports fiscal fourth-quarter 2016 financial results . Q4 earnings per share $0.32 . Q4 earnings per share view $0.37 -- Thomson Reuters I/B/E/S . Q4 adjusted earnings per share $0.36 .Q4 revenue $186.5 million versus I/B/E/S view $187.9 million.  Full Article

Myriad Genetics board approves additional $200 mln share repurchase program
Tuesday, 7 Jun 2016 

Myriad Genetics Inc : Myriad board approves $200 million increase in share repurchase program .Approved an additional $200 million authorization for its share repurchase program.  Full Article

Myriad acquires Sividon Diagnostics for 35 mln euros
Tuesday, 31 May 2016 

Myriad Genetics Inc : Myriad acquires Sividon Diagnostics . Has acquired Sividon Diagnostics for eur 35 million upfront with potential for eur 15 million in additional performance-based milestones .Myriad expects deal to be neutral to both revenue and earnings in fiscal year 2017.  Full Article

Myriad Genetics issues statement on HIPAA complaint
Thursday, 19 May 2016 

Myriad Genetics Inc : Complaint filed against co with department of health and human services on behalf of four individuals seeking their genetic testing results . "company only provides personal information that correlates to person who requested it" . "we believe complaint lacks merit and should not be accepted" .Believes it complied with the requests and provided thefour patients with designated record set, all requested personal health information.  Full Article

Myriad Genetics expands strategic research collaboration with AbbVie
Tuesday, 23 Feb 2016 

Myriad Genetics:Expands strategic research collaboration with AbbVie.Other terms of the deal were not disclosed.Under the terms of the agreement, AbbVie will use Myriad's CDx portfolio - myChoice HRD.  Full Article

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results